@abledoc @AskDrShashank The use of intravenous IVIg for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial in 59 patients. https://t.co/PIWTJY3cNW
IVIG "it should be considered in patients with > 30% involvement of lungs in lung CT scan, whom their dyspnea do not improve with standard treatment, those with persistent satO2< 90%, and those who develop aggravation of lung involvement in serial l
#medpeds thought: we give IVIG out like candy on these MIS-C children. The pathology is likely the similar with adults. We should be using it more. Open to others calling me crazy. https://t.co/2HG9E06Frs #covid19 #covid4mds
RT @julienpotet: 1/2 Small (n=59) RCT in Iran finds significantly lower mortality in severe #COVID19 receiving #IVIg (intravenous immunoglo…
RT @julienpotet: 1/2 Small (n=59) RCT in Iran finds significantly lower mortality in severe #COVID19 receiving #IVIg (intravenous immunoglo…
RT @julienpotet: 1/2 Small (n=59) RCT in Iran finds significantly lower mortality in severe #COVID19 receiving #IVIg (intravenous immunoglo…
RT @julienpotet: 1/2 Small (n=59) RCT in Iran finds significantly lower mortality in severe #COVID19 receiving #IVIg (intravenous immunoglo…
@KevinMccairn @4e6571
RT @julienpotet: 1/2 Small (n=59) RCT in Iran finds significantly lower mortality in severe #COVID19 receiving #IVIg (intravenous immunoglo…
RT @julienpotet: 1/2 Small (n=59) RCT in Iran finds significantly lower mortality in severe #COVID19 receiving #IVIg (intravenous immunoglo…
RT @julienpotet: 1/2 Small (n=59) RCT in Iran finds significantly lower mortality in severe #COVID19 receiving #IVIg (intravenous immunoglo…
1/2 Small (n=59) RCT in Iran finds significantly lower mortality in severe #COVID19 receiving #IVIg (intravenous immunoglobulin gamma) https://t.co/v77v8Z1Z2F https://t.co/p1bQC1fSfT
The use of intravenous #immunoglobulin gamma for the treatment of severe #COVID19: a randomized placebo-controlled double-blind #Clinicaltrial The in-hospital mortality rate was significantly lower in IVIg group compared to control group (20% vs. 48.3%).
「イランの非常に小規模なRCT(n=59)では、免疫グロブリンγの静脈内投与は有意な死亡率の有益性を示す。 aOR = 0.003 [95%CI: 0.001-0.815]; P = 0.042」
Results from a randomized placebo-controlled trial in Iran (n=59) suggest that administration of intravenous immunoglobin (IVIG) could reduce in-hospital mortality rates due to severe COVID-19 https://t.co/Dfq7uwyqBw